Key facts
- LenioBio’s last known valuation is $88.3M (Jul 2025).
- It has raised $51.9M; the latest was Later Stage VC ($5.8M) in Jul 2025.
- Notable investors include European Innovation Council, Coalition for Epidemic Preparedness Innovations, Bridford Group, Bundesministerium für Bildung und Forschung, EIT Health — 11 tracked in total.
- Status: Privately Held (backing).
Investors
11+- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for LenioBio
- ·The full record, as it builds
Funding rounds
No funding rounds for LenioBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About LenioBio
Developer of a synthetic biology and protein expression technology designed to accelerate and simplify protein expression for complex and novel proteins. The company offers a cell-free eukaryotic expression system compatible with linear deoxyribonucleic acid (DNA) and artificial intelligence-designed proteins, enabling biotech and pharmaceutical researchers to access post-translationally modified proteins without relying on cloning or cell lines.
- Sector
- Healthcare
- HQ
- Dusseldorf, Germany
- Founded
- 2016
- Employees
- 49
- Website
- leniobio.com/
- Ownership
- Privately Held (backing)
LenioBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in LenioBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on LenioBio in its N-PORT filings yet. We sweep new filings monthly.